Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 11, 2026, promoter Dr. Krishna Prasad Chigurupati sold 17,200,000 equity shares. This sale was conducted via a block deal and open market transactions to fund the second tranche of the company's preferential issue. The transaction reduced the aggregate shareholding of the promoter and promoter group from 38.02% to 31.08% of the paid-up equity capital. Dr. Chigurupati's individual holding decreased from 31.00% to 24.06%.
Granules India's cash flow from operating activities increased to ₹476.0 crore in March 2020 from ₹262.0 crore in March 2019. Consequently, free cash flow improved to ₹292.0 crore in March 2020, compared to a negative ₹17.0 crore in March 2019. Cash flow from operations (CFO/OP) also saw an increase to 113.0 in March 2020 from 91.0 in March 2019.
On September 15, 2026, promoter group members paid the remaining 75% subscription amount of ₹1,093 crore for convertible warrants. This made 2,49,14,530 warrants fully paid and eligible for conversion. Subsequently, on September 16, 2026, the company approved the allotment of 2,49,82,906 equity shares at ₹585 per share, totaling ₹1,461.50 crore, pursuant to the conversion of these warrants. This increased the paid-up equity share capital.
Granules India has shown growth in both sales and profit. Over the last 5 years, the compounded sales growth was 11%, and for the Trailing Twelve Months (TTM), it was 25%. Compounded profit growth over 5 years was 2%, with a significant increase to 36% for the TTM period.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 5 candles
Recent drawdown or price variability is high enough to warrant closer monitoring.
Primary driver: Price swings are higher than typical
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹1,476.77 crore | ₹1,470.61 crore | ₹1,387.94 crore | ₹1,296.99 crore | ₹1,210.11 crore |
| Profit Before Tax | ₹240.40 crore | PEAK₹262.36 crore | ₹202.23 crore | ₹175.87 crore | ₹144.53 crore |
| Profit Loss For Period | ₹179.96 crore | PEAK₹201.57 crore | ₹150.21 crore | ₹130.61 crore | ₹112.64 crore |
| Finance Costs | ₹21.12 crore | PEAK₹32.69 crore | ₹28.69 crore | ₹29.19 crore | ₹23.78 crore |
| Other Expenses | PEAK₹375.48 crore | ₹373.94 crore | ₹352.33 crore | ₹354.60 crore | ₹335.57 crore |
| Tax Expense | ₹60.44 crore | PEAK₹60.79 crore | ₹52.02 crore | ₹45.26 crore | ₹31.89 crore |
Revenue has risen steadily over the past four quarters, from ₹1,210.11 crore in Q1 FY2025-26 to ₹1,470.61 crore in Q4 FY2025-26. The latest quarter’s increase to ₹1,476.77 crore represents a sequential growth of only 0.4%, a marked deceleration from the 6–7% growth rates seen in the previous three quarters. The year-over-year growth of 22% is substantial, but the near-flat sequential movement suggests a pause in the revenue momentum.
Compared to Q1 FY2025-26, revenue grew 22%, profit before tax grew 66%, and net profit grew 60%. This indicates that the company has significantly improved its profitability over the past year. Basic earnings per share rose from ₹4.64 to ₹7.26, a 56% increase. The net profit margin improved from 9.3% in Q1 FY2025-26 to 12.2% in the current
Exchange disclosures and regulatory announcements for Granules India.
On September 16, 2026, Granules India Limited's Share Transfer and Stakeholders Relationship Committee approved the allotment of 2,49,82,906 fully paid-up equity shares (face value Re. 1 each) to four promoter group investors at an issue price of Rs. 585 per share, pursuant to conversion of warrants upon receipt of the balance 75% subscription amount. Total consideration received was Rs. 1,461.50 crores. Post-allotment, paid-up equity share capital increased from Rs. 24,77,96,921 to Rs. 27,27,79,827 (undiluted) and Rs. 27,27,96,921 (diluted). Allottees included Ms. Chigurupati Uma Devi (post-issue holding 12.51%), Ms. Chigurupati Priyanka (0.68%), Ms. Pragnya Chigurupati (0.69%), and Mr. Harsha Chigurupati (0.01%). 17,094 warrants issued to non-promoter investors remain outstanding for conversion.
On September 15, 2026, Granules India Limited disclosed that promoter group members paid the balance 75% subscription amount of Rs. 1,093 crores for convertible warrants issued via preferential allotment. Following this payment, 2,49,14,530 warrants issued to the promoter group are fully paid and eligible for conversion into equity shares. The company stated it will be in a net cash surplus position on a consolidated basis, enhancing flexibility to pursue growth and deploy capital ahead of originally envisaged timelines.
Granules India Limited announced a tentative analyst and investor meeting scheduled for September 18, 2026, in Hyderabad. The company confirmed that no unpublished price-sensitive information will be shared during the session and noted that the schedule is subject to change. The intimation was issued by Company Secretary Chaitanya Tummalia on September 11, 2026.
On September 11, 2026, promoter Dr. Krishna Prasad Chigurupati sold 17,200,000 equity shares of Granules India Limited via a block deal and open market to fund the second tranche of the company's ongoing preferential issue. The transaction reduced promoter and promoter group aggregate shareholding from 38.02% to 31.08% of paid-up equity capital, and Dr. Chigurupati's individual holding fell from 31.00% to 24.06%. The company stated the funds from the February 2026 preferential issue were deployed faster than anticipated for growth initiatives aligned with the issue's stated objects.
Effective August 13, 2026, Granules India Limited internally transferred Mr. Sanjay Kumar from his role as Chief Strategy Officer to become the Chief Executive Officer of its wholly owned subsidiary, Ascelis Peptides Private Limited. This change was formalized through a resignation letter submitted by Mr. Kumar and an official intimation to the National Stock Exchange and BSE Limited pursuant to SEBI Listing Regulations.
On August 13, 2026, Granules India Limited reported the resignation of Sanjay Kumar as Chief Strategy Officer, effective the same day, due to an internal transfer to a wholly owned subsidiary.
Granules India Limited has informed the Exchange about Resignation of Director/KMP/SMP |SUBJECT: Resignation of Director/KMP/SMP
Granules India Limited held its 35th Annual General Meeting on August 6, 2026, via video conferencing. The meeting transacted ordinary business, including the adoption of audited financial statements for FY 2025-26, the declaration of a final dividend of Rs. 1.75 per equity share, and the re-appointment of Ms. Priyanka Chigurupati. All resolutions were passed with the requisite majority, as confirmed by the consolidated scrutinizer's report.
Recent market and company developments associated with Granules India.
Trade Spotlight
HYDERABAD: Krishna Prasad Chigurupati, the promoter of Hyderabad-based Granules India, offloaded a nearly 7% (1.72 crore shares) stake in the company .
Several Indian companies, including Reliance and Infosys, are making significant moves, from fundraising to new facilities, highlighting a dynamic shift in the corporate landscape
Indian stock market indices, Sensex and Nifty 50, are set to open higher on 15 September amid mixed global signals. Sensex and Nifty ended lower previously, but GIFT Nifty shows a positive start. Crude oil prices remain a concern for market stability.
On September 11, Indian stock markets experienced a remarkable bounce back after an initial dip at opening. Key index heavyweights attracted selective buying, which limited the days overall losses. Major players like HDFC Bank and IT sectors remained in focus amid relevant corporate announcements. Additionally, SEBI's discussion paper regarding the Closing Auction Session received input on five critical areas.
MarketSmith India reveals its top stock recommendations for today, 15 September. Get expert insights into the best-performing stocks to guide your investment decisions.
From HDFC Bank's succession plan to Tata Sons' potential listing and its impact on listed Tata Group stocks and the impact of SEBI's consultation paper on CAS on BSE, Angel One and other brokers, these are the stocks you should watch out for going into Tuesday's trading session.
Paytm parent One97 Communications hit a post-listing record high of ₹1,807.5, while Granules India promoter Krishna Prasad Chigurupati offloaded a 6.95% stake for ₹1,501 crore in block deals
Comprehensive Section Breakdown for Granules India
Strategic Vision: Vertically integrated pharmaceutical company manufacturing APIs, PFIs, and FDs.
• Vertically integrated pharmaceutical manufacturing capabilities.
• Focus on cost-effective product development through R&D.
• Expansion into specialized therapeutic segments like Oncology.
• Development of advanced drug delivery systems.
Granules India reported revenue of ₹1,476.77 crore for the June 2026 quarter, a marginal 0.4% increase from the preceding quarter and a 22% rise from the same period last year. Profit before tax fell 8.4% sequentially to ₹240.40 crore, even as finance costs dropped 35%. Net profit declined 10.7% to ₹179.96 crore, with the effective tax rate rising to 25.1% from 23.2%. Year-over-year, profit grew significantly, reflecting improved margins.
Profit before tax fell from ₹262.36 crore in Q4 FY2025-26 to ₹240.40 crore in Q1 FY2026-27, a decline of 8.4%. Net profit dropped from ₹201.57 crore to ₹179.96 crore, a decline of 10.7%. This occurred even as finance costs decreased sharply from ₹32.69 crore to ₹21.12 crore, a 35% reduction. Other expenses increased marginally from ₹373.94 crore to ₹375.48 crore. The effective tax rate also increased from 23.2% to 25.1%, further reducing net profit. As a result, the net profit margin fell from 13.7% in Q4 to 12.2% in Q1.
Category: Manufacturing
Granules India is a manufacturer of first-line defense APIs, including paracetamol, metformin, ibuprofen, guaifenesin, and methocarbamol.
Category: Manufacturing
The company pioneered the commercialization of PFIs for large-volume drugs within the pharmaceutical value chain.
Category: Manufacturing
Granules India provides multiple finished dosage forms, such as tablets, caplets, and press-fit capsules, offered in bulk, blister packs, and bottles.
Category: Manufacturing
Granules India has expanded its portfolio by venturing into the Oncology Therapeutic segment, where it develops APIs that are forward-integrated into finished dosages.
Core Thesis: A vertically integrated value chain supports operations from API manufacturing to finished dosage forms.
• Vertical Integration: The company operates with a vertically integrated model, evolving from an API manufacturer to a global pharmaceutical player. • Research and Development: Strong R&D facilities and a dedicated team focus on developing processes and products for cost-effective offerings. • Advanced Pharmaceutical Solutions: Developing capabilities in Complex Multiple Unit Pellet System (MUPS) and effective delivery systems for modified and delayed-release technologies.